Investigation of transrenal KRAS mutation in late stage NSCLC patients correlates to disease progression

References

• Ahrendt, S.A., et al., 2001. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92, 1525–1530.
   PubMed Web of Science ®Google Scholar
• Anker, P., et al., 1999. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 18, 65–73.
   PubMed Web of Science ®Google Scholar
• Bhattacharya, S., Socinski, M.A., and Burns, T.F. 2015. KRAS mutant lung cancer: progress thus far on an elusive therapeutic target. Clin Transl Med 4, 35.
   PubMed Web of Science ®Google Scholar
• Bos, JL. 1989. Ras oncogenes in human cancer: a review. Cancer Res 49, 4682–4689.
   PubMed Web of Science ®Google Scholar
• Chen, S., et al., 2016. Urinary circulating DNA detection for dynamic tracking of EGFR mutations for NSCLC patients treated with EGFR-TKIs. Clin Transl Oncol. [Epub ahead of print]. doi: 10.1007/s12094-016-1534-9.
   Web of Science ®Google Scholar
• Diehl, F., et al., 2008. Circulating mutant DNA to assess tumor dynamics. Nat Med 14, 985–990.
   PubMed Web of Science ®Google Scholar
• Gevensleben, H., et al., 2013. Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 19, 3276–3284.
   PubMed Web of Science ®Google Scholar
• Guibert, N., et al., 2016. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. Lung Cancer 100, 1–4. doi: 10.1016/j.lungcan.2016.07.021.
   PubMed Web of Science ®Google Scholar
• Jahr, S., et al., 2001. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61, 1659–1665.
   PubMed Web of Science ®Google Scholar
• Jekunen, A.P., 2015. Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments. J Oncol 2015, 809835.
   PubMed Web of Science ®Google Scholar
• Johnson, D.H., Schiller, J.H., and Bunn, P.A. 2014. Recent clinical advances in lung cancer management. J Clin Oncol 32, 973–982.
   PubMed Web of Science ®Google Scholar
• Mahoney, C.L., et al., 2009. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer 100, 370–375.
   PubMed Web of Science ®Google Scholar
• Massarelli, E., et al., 2007. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non–small-cell lung cancer. Clin Cancer Res 13, 2890–2896.
   PubMed Web of Science ®Google Scholar
• Nygaard, A.D., et al., 2013. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer 79, 312–317.
   PubMed Web of Science ®Google Scholar
• Ofiara, L.M., et al., 2012. The importance of a satisfactory biopsy for the diagnosis of lung cancer in the era of personalized treatment. Curr Oncol 19, 16–23.
   PubMed Web of Science ®Google Scholar
• Okimoto, R.A. and Bivona, T.G., 2014. Recent advances in personalized lung cancer medicine. Pers Med 11, 309–321.
   PubMed Web of Science ®Google Scholar
• Paez, J.G., et al., 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500.
   PubMed Web of Science ®Google Scholar
• Pathak, A.K., et al., 2006. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52, 1833–1842.
   PubMed Web of Science ®Google Scholar
• Riely, G.J., et al., 2011. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 9, 1328–1330.
   PubMed Web of Science ®Google Scholar
• Roberts, P.J. and Stinchcombe, T.E., 2013. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31, 1112–1121.
   PubMed Web of Science ®Google Scholar
• Santos, E., et al., 1984. Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science 223, 661–664.
   PubMed Web of Science ®Google Scholar
• Shaw, A.T., et al., 2014. Crizotinib in ROS1-rearranged non–small-cell lung cancer. New Engl J Med 371, 1963–1971.
   PubMed Web of Science ®Google Scholar
• Su, Y.H., et al., 2004. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn 6, 101–107.
   PubMed Web of Science ®Google Scholar
• Suleiman, A.A., et al., 2015. Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib. J Thorac Oncol 10, 84–92.
   PubMed Web of Science ®Google Scholar
• Taly, V., et al., 2013. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem 59, 1722–31.
   PubMed Web of Science ®Google Scholar
• Tsao, S.C.H., et al., 2015. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep 5, doi: 10.1038/srep11198.
   Web of Science ®Google Scholar
• Ueda, M., et al., 2008. Mutational analysis of the BRAF gene in human tumor cells. Human Cell 21, 13–17.
   PubMed Web of Science ®Google Scholar
• Van Cutsem, E., et al., 2011. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29, 2011–2019.
   PubMed Web of Science ®Google Scholar
• Zhou, C., et al., 2011. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12, 735–742.
   PubMed Web of Science ®Google Scholar